Scandicain en es it fr

Scandicain Brand names, Scandicain Analogs

Scandicain Brand Names Mixture

  • No information avaliable

Scandicain Chemical_Formula


Scandicain RX_link

Scandicain fda sheet

Scandicain FDA

Scandicain msds (material safety sheet)

Scandicain MSDS

Scandicain Synthesis Reference

No information avaliable

Scandicain Molecular Weight

129.164 g/mol

Scandicain Melting Point

223-226 oC

Scandicain H2O Solubility

Freely soluble as HCl salt

Scandicain State


Scandicain LogP


Scandicain Dosage Forms

Extended release tablet (500 mg or 1000 mg)

Scandicain Indication

For use as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes.

Scandicain Pharmacology

Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease.

Scandicain Absorption

Absorbed over 6 hours, bioavailability is 50 to 60% under fasting conditions. Food delays absorption.

Scandicain side effects and Toxicity

Acute oral toxicity (LD50): 350 mg/kg [Rabbit]. It would be expected that adverse reactions of a more intense character including epigastric discomfort, nausea, and vomiting followed by diarrhea, drowsiness, weakness, dizziness, malaise and headache might be seen.

Scandicain Patient Information

Scandicain Organisms Affected

Humans and other mammals